Achaogen  General Information Business: We are a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE. In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action.” We expect to initiate a Phase 3 superiority trial of plazomicin in the first quarter of 2014. Through the Special Protocol Assessment procedure, the U.S. Food and Drug Administration, or FDA, has agreed that the design and planned analyses of our single pivotal Phase 3 trial adequately address objectives in support of a New Drug Application. We have also received FDA fast track designation for the development and regulatory review of plazomicin to treat serious and life-threatening CRE infections. Our plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority for up to $103.8 million. Industry: PHARMACEUTICAL PREPARATIONS Employees: 39 Founded: 2002 Contact Information Address: 7000 Shoreline Court, Suite 371, South San Francisco, CA 94080, US Phone: 650-800-3636 Web Address: www.achaogen.com View Prospectus: Achaogen Financial Information Market Cap: $ 205.14 mil Revenues: $ 18.5 mil (last 12 months) Net Income: $ -13.1 mil (last 12 months) IPO Profile Symbol: AKAO Shares (millions): 6.0 Price Range: $12.00 - $12.00 Est.$ Volume $ 72.0 mil Manager / Joint Managers Credit Suisse/ Cowen and Company Co Managers William Blair/ Needham & Company Expected to Trade 3/12/2014 Status Priced SCOOP RATING Available only to Subscribers RATING CHANGE Available only to Subscribers